Overactivation of KDM4B has been noted in prostate cancer, while KDM4C overexpression was initially identified in esophageal, lung, and breast cancers.118–120 Additionally, the overexpression of KDM5B has been noted in prostate cancer. Here, KDM5B is linked to breast cancer.